Drug Profile
PA 1297
Alternative Names: PA-1297Latest Information Update: 11 Jun 2001
Price :
$50
*
At a glance
- Originator Chiron Corporation
- Class Antibacterials; Antituberculars; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 11 Jun 2001 No-Development-Reported for Tuberculosis in USA (Unknown route)
- 05 Oct 2000 PathoGenesis Corporation has been acquired by Chiron Corporation
- 20 Jan 1998 New profile